Abbott, AstraZeneca terminate agreement for diabetes drug Dapagliflozin in India
New Delhi: Drug major AstraZeneca Pharma India on Friday said it has terminated its distribution agreements with Abbott Healthcare for type 2 diabetes medicine Dapagliflozin in India.
"AstraZeneca India and Abbott have mutually terminated the distribution agreement on May 27, 2021," AstraZeneca India said in a regulatory filing.
AstraZeneca India will continue to independently market Dapagliflozin, the combinations of Dapagliflozin and Metformin as well as Dapagliflozin and Saxagliptin in India under the brand names Forxiga, Xigduo and Qtern respectively, the filing said.
Read also: Pfizer jab after first AstraZeneca dose safe and highly effective: Study
On December 7, 2018, AstraZeneca Pharma India and Abbott Healthcare had entered into a distribution agreement for the distribution of Dapagliflozin.
Under the said agreement, Abbott promoted and distributed Dapagliflozin under the brand name "Gledepa" and the combination of Dapagliflozin with Metformin under the brand name "Gledepa Met". Please note that by virtue of the said Distribution Agreement, Abbott had not been conferred with any license to the patents over the drugs comprising Dapagliflozin, and the license granted to Abbott was with respect only to the use of the trademarks "Gledepa" and "Gledepa Met"
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.